Olema Pharmaceuticals, Inc.
OLMAHealthcareNASDAQBiotechnology · Last scanned May 29, 2026
Scan Results
Daily timeframe2 of 4 indicators bearish as of May 28
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. At a $1.11B market cap, Olema Pharmaceuticals, Inc. ranks as a small-cap company within healthcare. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.
Market Cap
$1.11B
Beta
2.06
P/E (TTM)
—
P/E (Fwd)
-5.49
EPS (TTM)
$-2.03
EPS (Fwd)
$-2.33
ROE
-42.9%
ROA
-25.5%
Cash
$505.3M
Total Debt
$4.0M
Free CF
-$78.8M
52W Change
141.7%
Annual Financials
Cash vs Debt
Olema Pharmaceuticals, Inc. holds $505.3M in cash against $4.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$78.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -42.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Olema Pharmaceuticals, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, OLMA has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Olema Pharmaceuticals, Inc. and its sector.